1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance [TA269] Published date: 12 December 2012 Last updated: 01 January 2015

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • Appendix A: Appraisal Committee members, and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

6 Related NICE guidance

  • Published
  • Under development

6 Related NICE guidance

Published

  • Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma. NICE technology appraisal guidance 268 (2012).

  • Skin cancer prevention: information, resources and environmental changes. NICE public health guidance 32 (2011).

  • Improving outcomes for people with skin tumours including melanoma. NICE cancer service guidance (2006).

  • Referral guidelines for suspected cancer. NICE clinical guideline 27 (2005).

  • Improving supportive and palliative care for adults with cancer. NICE cancer service guidance (2004).

Under development

NICE is developing the following guidance:

  • Ipilimumab in combination with dacarbazine for previously untreated unresectable stage III or IV malignant melanoma (expected date of publication August 2013).

  • National Institute for Health and Care Excellence (NICE)

  • Next